7UX.F SPAGO NANOMEDICAL AB
- Market cap
- EUR 2.87M
- P/E
- -
- P/B
- 1.05x
- ROE
- -89.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7UX.F undervalued?
Graham numberThe Graham number of SPAGO NANOMEDICAL AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SPAGO NANOMEDICAL AB fundamental analysis
No fundamental analysis for SPAGO NANOMEDICAL AB yet.
SPAGO NANOMEDICAL AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SPAGO NANOMEDICAL AB
Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a …
Full company profileSPAGO NANOMEDICAL AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SPAGO NANOMEDICAL AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.05M | 1.20M | 1.91M | 437K | 44.0K |
| Gross Profit | -15.6M | -23.3M | -12.4M | -11.0M | -13.2M |
| Operating Income | -39.1M | -42.5M | -33.4M | -26.5M | -28.6M |
| EBITDA | -38.7M | -42.2M | -32.2M | -26.4M | -28.5M |
| Net Income | -39.2M | -42.2M | -32.5M | -26.6M | -28.3M |
| EPS | -0.41 | -0.22 | -0.09 | -0.04 | -0.04 |
| Balance Sheet | |||||
| Total Assets | 206M | 53.0M | 39.6M | 36.7M | 37.7M |
| Total Liabilities | 8.80M | 11.7M | 6.35M | 5.94M | 5.99M |
| Shareholders' Equity | 197M | 41.3M | 33.2M | 30.7M | 31.7M |
| Cash & Short-term Investments | 62.1M | 45.2M | 32.5M | 29.7M | 32.5M |
| Cash Flow | |||||
| Operating Cash Flow | -38.2M | -44.9M | -34.7M | -28.3M | -23.1M |
| Capital Expenditure | 3.83M | 506K | 230K | 229K | 0.00 |
| Free Cash Flow | -42.0M | -45.4M | -34.7M | -28.5M | -23.1M |
| Ratios | |||||
| ROE | -19.9% | -102.2% | -97.8% | -86.4% | -89.2% |
| ROA | -19.0% | -79.7% | -82.1% | -72.4% | -75.0% |
| Net Profit Margin | -3,718.9% | -3,509.8% | -1,701.2% | -6,076.4% | -64,222.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SPAGO NANOMEDICAL AB dividends
SPAGO NANOMEDICAL AB has not paid dividends in the last 4 fiscal years.
Who owns SPAGO NANOMEDICAL AB
- Insiders 70.07%
- Institutions 8.96%
- Public & others 20.98%
- Shares outstanding 798M
- Free float 283M
SPAGO NANOMEDICAL AB company profile
- Company name
- SPAGO NANOMEDICAL AB
- Ticker
- 7UX.F
- ISIN
- SE0004899474
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- ScheelevAegen 22, Lund, Sweden, 223 63
- Phone
- 46 4 68 11 88
- Website
- spagonanomedical.se
About SPAGO NANOMEDICAL AB
Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of cancer. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.
SPAGO NANOMEDICAL AB management
3- Dr. Mats Hansen M.Sc., Ph.D.Chief Executive Officer · born 1971
- Ms. Hanna Olsson M.Sc.Chief Financial Officer · born 1980
- Mr. Paul HargreavesChief Development Officer · born 1969